3 assets in Anaplastic Pleomorphic Xanthoastrocytoma

Therapeutic assets addressing Anaplastic Pleomorphic Xanthoastrocytoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Trametinib Anaplastic Pleomorphic Xanthoastrocytoma	National Cancer Institute (NCI)	P4	BB (69)
Dabrafenib Anaplastic Pleomorphic Xanthoastrocytoma	National Cancer Institute (NCI)	P4	BB (65)
Onc 206 Anaplastic Pleomorphic Xanthoastrocytoma	Jazz Pharmaceuticals	P1	CC (43)